Revenue Recognition (Tables)

6 Months Ended

Jun. 30, 2022

Revenue from Contract with Customer [Abstract]

Schedule of Contract Assets and Liabilities

The following table summarizes the values of contract assets, capitalized commissions and contract liabilities (in thousands):

	June 30, 2022		December 31, 2021
Current pharma contract assets (1)	$	1,951	$	1,738
Long-term pharma contract assets (2)	283		236
Total pharma contract assets	$	2,234	$	1,974
Current pharma capitalized commissions (1)	$	128	$	109
Long-term pharma capitalized commissions (2)	1,139		882
Total pharma capitalized commissions	$	1,267	$	991
Current pharma contract liabilities	$	6,348	$	5,192
Long-term pharma contract liabilities (3)	1,121		917
Total pharma contract liabilities	$	7,469	$	6,109

(1) Current pharma contract assets and Current pharma capitalized commissions are classified as other current assets on the Consolidated Balance Sheets.

(2) Long-term pharma contract assets and Long-term pharma capitalized commissions are classified as other assets on the Consolidated Balance Sheets.

(3) Long-term pharma contract liabilities are classified as other long-term liabilities on the Consolidated Balance Sheets.

Schedule of Disaggregation of Revenue

The following table details the disaggregation of revenue for both the Clinical and Pharma Services Segments (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Clinical Services:
Client direct billing	$	69,874	$	63,137	$	134,888	$	123,846
Commercial Insurance	18,512		20,528		36,800		39,102
Medicare and Medicaid	17,167		17,484		32,632		34,634
Self-Pay	82		256		106		310
Total Clinical Services	$	105,635	$	101,405	$	204,426	$	197,892
Pharma Services:	19,437		20,319		37,815		39,365
Total Revenue	$	125,072	$	121,724	$	242,241	$	237,257